Doud­na-found­ed CRISPR up­start bags $45M for new Cas re­search, ex­tends its reach in­to ther­a­peu­tics

The South San Fran­cis­co-based CRISPR up­start that set out to de­vel­op di­ag­nos­tics un­der co-founder Jen­nifer Doud­na’s guid­ance is back with $45 mil­lion in fund­ing — and new am­bi­tions in ther­a­peu­tics.

Mam­moth Bio­sciences is al­so putting its tech to the test amid height­ened vig­i­lance sur­round­ing the nov­el coro­n­avirus emerg­ing out of Wuhan, Chi­na. The goal is to pro­to­type a rapid mol­e­c­u­lar test that can be used at point of care.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER